Current methods for gene delivery may result in limited viability and efficacy
Current gene delivery struggles to target primary naïve T and B cells efficiently while maintaining their naïve state, limiting therapeutic efficacy. Existing methods fail to deliver genetic material without cell pre-activation or manipulate multiple miRNAs within the same cell, resulting in reduced viability and efficacy, leading to T cell exhaustion.
This innovation enables efficient delivery of multiple genetic materials to naïve immune cells, preserving their naïve state. It enhances cell viability and modulation post-delivery, inducing specific changes for optimized immune responses, offering superior protection against intracellular pathogens.
New nanowire platform increase efficacy to improve treatment
This technology utilizes a functionalized nanowire platform to deliver multiple genetic materials, including CRISPR and microRNAs, directly to naïve T and B cells without pre-activation, retaining their naïve state. This approach allows precise control over the immune cells' programming to increase their efficacy in adoptive cell therapy, offering a significant leap forward in treating various maladies through immune system modulation.
- Efficient gene delivery to naïve immune cells.
- Induced specific changes in treated cells
- Preserve immune cells’ naïve state.
- Enhance protection against intracellular pathogens
- Improve cell viability post-delivery
• Adoptive T cell therapy
• Research tool for immune cell manipulation across species, ages, and subtypes.
• Enhanced immune protection strategies against intracellular pathogens